🏛️ Verified NIH Record • Updated 2026-07-29

Study of BHV-1300 in Graves' Disease (NCT06980649)

🟢 Recruiting Phase1 💊 Investigational Drug / Biologic Sponsor: Biohaven Therapeutics Ltd.

🩺 Plain-English Summary (8th-Grade Level)

The purpose of this study is to determine if BHV-1300 is a safe treatment in participants with Graves' Disease and to explore its effect on disease-specific biomarkers.

Who can join: Review the eligibility criteria below.

Location: Site-103 — South Gate, California

📋 "Do I Qualify?" — 1-Minute Self Screener

Instant Checklist

Full eligibility criteria are available on the official NIH protocol. View the criteria ↗

📍 All Participating Trial Locations (18 Sites)

  • Site-103 — South Gate, California
  • Site-100 — Miami, Florida
  • Site-104 — Columbus, Georgia
  • Site-108 — Greenville, North Carolina
  • Site-110 — Canton, Ohio
  • Site-107 — Memphis, Tennessee
  • Site-109 — Dallas, Texas
  • Site-106 — Houston, Texas
  • Site-101 — Houston, Texas
  • Site-105 — Shavano Park, Texas
  • Site-004 — Fitzroy,
  • Site-011 — Herston,
  • Site-001 — Kotara,
  • Site-003 — Melbourne,
  • Site-010 — Oaklands Park,
  • Site-008 — Parkville,
  • Site-006 — St Leonards,
  • Site-002 — Torquay,

💰 Cost, Insurance & Patient Rights

  • 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
  • Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
  • Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
🏛️ View Official NIH Record ↗